Confined or spread disease-Spread beyond the prostate gland Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread beyond the prostate gland Posts on Medivizor

Evaluating docetaxel plus hormone therapy for the treatment of metastatic prostate cancer

Posted by on Nov 3, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of docetaxel (Taxotere) plus hormone therapy for patients with metastatic prostate cancer (cancer that spread outside the prostate). This study found that this treatment combination improved survival for these patients, regardless of tumor burden. Some background One treatment for...

Read More

Evaluating the overall survival in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Posted by on Oct 27, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated the effect of apalutamide (Erleada) on survival in patients with castrate-resistant prostate cancer (CRPC). This study found that apalutamide had a positive effect on the survival of these patients. Some background One treatment option for patients with prostate cancer is androgen deprivation therapy...

Read More

Looking for patients with advanced prostate cancer to test a new treatment strategy

Posted by on Oct 24, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 2 study will investigate cryosurgical freezing (CF) and intratumoral combination immunotherapy (ITI) in advanced prostate cancer (PC). The main outcome will be the reduction in prostate specific antigen (PSA). This trial is recruiting in California and Michigan, US. The details Metastatic prostate cancer (PC) is an...

Read More

Can apalutamide improve outcomes for patients with metastatic, castration-sensitive prostate cancer?

Posted by on Oct 22, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated whether adding apalutamide (erleada) to androgen-deprivation therapy (ADT) would improve survival in patients with prostate cancer. The authors concluded that adding apalutamide to ADT improved outcomes for these patients. Some background Androgen deprivation therapy (ADT) is the standard treatment for patients...

Read More

What are the outcomes of sipuleucel-T treatment for patients with metastatic castration-resistant prostate cancer?

Posted by on Oct 1, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated the safety and effectiveness of sipuleucel-T (Provenge) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The authors found that the average survival after sipuleucel-T treatment was 30.7 months and that 13.7% of patients experienced side effects. Some background...

Read More

Searching for patients with advanced prostate cancer to test an experimental medication

Posted by on Sep 30, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 2 study will investigate the safety and effectiveness of AZD4635 in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The main outcome will be the objective response rate (ORR) and prostate-specific antigen (PSA; a marker of prostate cancer) response. This trial is recruiting in multiple...

Read More

Looking for patients with advanced prostate cancer to test a new treatment

Posted by on Sep 10, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with advanced solid tumors such as prostate cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...

Read More

Evaluating enzalutamide plus androgen deprivation therapy to treat metastatic prostate cancer

Posted by on Aug 31, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) with androgen deprivation therapy (ADT) in metastatic prostate cancer. This study found that this combination was associated with longer progression-free and overall survival compared to ADT alone. Some background Patients...

Read More

Looking for patients with advanced prostate cancer to test a new drug

Posted by on Jul 21, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to address this. Immune...

Read More